Lancet

The most recent articles from: Lancet

Lancet · Jan 2024

Letter

A call to action for equitable care for trans and non-binary people.

no abstract available

expand abstract… or not…
Lancet · Jan 2024

Coronary embolisation of native aortic valve debris during transcatheter aortic valve replacement: mechanical embolectomy and histopathological analysis.

no abstract available

keep going… or just mark as read…
Lancet · Jan 2024

Comment Letter

All children pay the price for antisemitic bias.

no abstract available

expand abstract… mark as read…
Lancet · Jan 2024

Editorial Comment

Time for renewed optimism for schizophrenia?

no abstract available

expand abstract… or not…
Lancet · Jan 2024

Randomized Controlled Trial

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms in patients with H1-antihistamine (H1-AH) refractory CSU. Here, we report the efficacy and safety outcomes from two ligelizumab phase 3 studies. ⋯ Novartis Pharma.

expand abstract… mark as read…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.